Moleculin Biotech, Inc. (MBRX)
| Market Cap | 12.80M +326.6% |
| Revenue (ttm) | n/a |
| Net Income | -51.41M |
| EPS | -76.14 |
| Shares Out | 5.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 546,105 |
| Open | 2.610 |
| Previous Close | 2.680 |
| Day's Range | 2.410 - 2.620 |
| 52-Week Range | 2.410 - 44.000 |
| Beta | 1.67 |
| Analysts | Strong Buy |
| Price Target | 105.50 (+4,188.62%) |
| Earnings Date | Mar 20, 2026 |
About MBRX
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for MBRX stock is "Strong Buy." The 12-month stock price target is $105.5, which is an increase of 4,188.62% from the latest price.
News
Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds
HOUSTON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has entered into agreements with certain holders of its existing w...
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)
Preliminary blinded CR rate showed 67% improvement over historical cytarabine response Roughly 35% of the subjects treated to date represent ventoclax regimen failures First 45 subjects treated on tra...
Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin
HOUSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the Japan Patent Office (JPO) has issued a notice of allowance f...
Moleculin Launches CEO Corner Platform to Share Strategic Insights
CEO Corner segments intended to provide added perspective to press releases, clinical trial developments and pipeline progress Provides interested parties with the ability to connect with the Company ...
Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
– Live video webcast on Wednesday, February 11 th at 1:20 PM EST
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects
– Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials – This next-generation anthracycline demonstrates safety and promising early activity in treating multip...
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs
– First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries – Investigator-Initiated (IIT) funded pancreatic and brain cancer trials HOUSTON, Jan. 12, 2026 (GLOBE NEWSWIRE...
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors
Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta Results demonstrated WP1066 induces anti-tumor immune r...
Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds
HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeti...
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026
Continues to drive enrollment with increase to 78% now consented Blinded response activity tracking within expected range
Moleculin Announces New Annamycin Collaboration in Brain Tumors
Investigator-Initiated Preclinical studies at CIC biomaGUNE aimed at combatting Glioblastoma Multiforme Research will evaluate effects of intra-arterial delivery of Annamycin HOUSTON, Dec. 08, 2025 (...
Moleculin to Participate in the Virtual Investor Closing Bell Series
Live video webcast with Walter Klemp, Chairman and Chief Executive Officer, on Tuesday, December 2 nd at 4:00 PM ET
Moleculin Announces Reverse Stock Split
HOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it filed an amendment to its amended and restated certificate of...
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented
Completion of treatment for the first 45 patients on pace for Q1 2026 with initial unblinded data thereafter; blinded response activity tracking within expected range
Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill
Preclinical research to be conducted at the University of North Carolina at Chapel Hill (UNC) Annamycin will be used in conjunction with novel agents and modalities Preclinical studies indicate Annam...
Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting
HOUSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeti...
Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin
HOUSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeti...
Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer
Atlantic Health, a leading provider of health care based in New Jersey, to conduct the investigator-initiated Phase 1B/2 study Preclinical studies indicate Annamycin targets key factors in pancreatic ...
Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin
HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates target...
Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial
European expansion in September across Georgia, Italy, Lithuania, Poland, Romania, Spain, and US 13 subjects recruited (treated, enrolled, or screened) Forecasts total recruitment of 20 or more subjec...
Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia
Spain site opens with two R/R AML subjects enrolled; One treated On track to recruit 45 subjects in 4Q25 for initial data unblinding HOUSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc....
Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds
HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeti...
Moleculin Issues New Positive AML Overall Survival Data:
Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8) Median OS of 2 nd Line efficacy evaluable population of 12 months (n=9) Median OS of Intent to Treat population (1L...
Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
– Live video webcast on Wednesday, August 20 th at 2:00 PM ET HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceut...
Moleculin Reports Second Quarter 2025 Financial Results and Highlights
- Continues recruitment and opens US and EU sites for the Phase 2B/3 MIRACLE trial - 20+ additional clinical sites in Europe and the US expected to begin recruitment by the end of Q3